Abstract: Neoadjuvant chemotherapy (NAC) applied prior to surgical excision of the tumor has become a frequently used therapeutic approach in patients with operable and inoperable breast cancer. Such chemotherapy alters the morphology of breast cancers and normal breast tissue. Thus it is important for pathologists to become familiar with these changes and to know how to handle and assess breast specimens after neoadjuvant chemotherapy. Evaluation of the therapeutic response and measurement of residual disease is important in the pathologic assessment of the final surgical resection specimens because these data help in predicting patient's chances for cure and survival, and also provide guidance for further therapy. This review will discuss treatment effects and demonstrate how to evaluate, sample and measure residual breast cancer in excision specimens including axillary lymph nodes.
INTRODUCTION
Neoadjuvant chemotherapy, implying that the patient will receive chemotherapy before the complete surgical removal of the carcinoma, has been of recent the standard of care for the treatment of locally advanced breast cancer [1] . One of the major benefits of neoadjuvant chemotherapy is that it can diminish large cancers enabling the surgeon to remove the residual tumor by a more limited operation, such as lumpectomy, instead of mastectomy. The response to neoadjuvant chemotherapy may provide some indication about the potential response of the tumor to further treatment and in general may be informative about the biology of the carcinoma under treatment. Since the recent data and a metaanalysis of the published results showed no difference between neoadjuvant therapy and adjuvant therapy in terms of survival and overall disease progression, neoadjuvant chemotherapy can be offered as a standard treatment or as an alternative to adjuvant treatment to all patients who are expected to receive chemotherapy for their cancers [2] .
Assessment of the therapeutic response and measurement of residual disease in the breast and/or axillary lymph node is important because it may predict survival and provide guidelines for further therapy [3, 4] . Complete clinical regression does not imply complete pathologic response (cPR). Between 60-80% of patients considered to have a clinical complete response have residual tumor detected by pathologists in the surgical specimens. On the other hand, about 20% of patients with clinically suspected residual disease have complete pathologic response after microscopic examination [5] . Therefore, pathologic assessment of the final surgical resection specimen is still the gold standard for determining a complete response. 
HANDLING OF SURGICAL RESECTION SPECIMENS AFTER NEOADJUVANT CHEMOTHERAPY
Before the examination and sampling of the surgical resection specimen it is absolutely essential to obtain as many clinical data as possible, including the radiologic report. Under ideal conditions mammography X-Rays should be sent to the pathologist together with the surgical specimen, or the pathologist should have access to the mammograms through the hospital interdepartmental information technology system. The essential data include:
•
The histologic diagnosis on the pre-treatment core biopsy.
• Axillary lymph node status.
• The length of chemotherapy and the drugs that were used.
• The size and location of the tumor prior and after chemotherapy.
• Clinical and radiologic impression of the treatment response.
Mastectomy Specimen
The mastectomy specimen should be received fresh with a mark indicating the axillary tail. Detailed clinical information including the pretreatment tumor size and location and post-treatment radiologic imaging finding are absolutely essential before examining the specimen. If lesions are thought to be multiple it is imperative to have the mammogram or at least a detailed radiology report describing the mammography data.
The posterior surface (deep margin) of the mastectomy specimen is inked. The specimen is serially sectioned at a 5 mm interval from the posterior surface leaving the skin intact. The cut surface is examined for evidence of tumor (tumor bed), residual tumor and previous biopsy site, especially at the locations corresponding to the radiology report. Grossly, the tumor bed appears as a poorly defined fibrotic area or simply fibrotic streaks; the residual tumor appears as fleshy nodules or areas. The tumor bed size and distance to margins should be measured. If a patient has had an excellent response to neoadjuvant chemotherapy, a gross lesion may not be detected, and the specimen may be sent to radiology for X-Ray to identify the previous biopsy clip (if was placed previously).
The sampling method and number of blocks taken vary among institutions and are dependent on the size of the specimen and the size of the lesion. In general, the previous tumor bed should be sampled extensively; additional or entire sampling may be necessary if the initial sections don't show microscopic residual tumor.
Lumpectomy Specimen (Wide Local Excision)
The lumpectomy specimen should be received fresh and oriented. The specimen should be measured in three dimensions and inked in six colors marking superior/inferior, medial/lateral and anterior/posterior margins. Then the specimen is serially sectioned perpendicular to the long axis of the specimen at a 3 mm interval. The slices are laid out and carefully examined. If a gross lesion or tumor bed is seen, the lesion size and distance to all six margins are recorded. Any close margins (less than 2 mm) should be reported to the surgeon right away for possible immediate reexcisions. The sampling method and the number of blocks taken vary among institutions and are dependent on the size of the specimen and the size of the lesion. In general (at our institution), if no gross lesion/tumor bed is seen, the entire specimen is submitted to look for microscopic residual tumor. If there is a gross lesion/tumor bed, then the entire lesion is submitted and its distance to margins documented. Only representative sections of the remaining grossly unremarkable specimen are submitted.
Axillary Lymph Nodes
The axillary lymph node sample may include sentinel lymph node or axillary lymph node dissection after neoadjuvant chemotherapy. The specimen is handled the same way as for lymph node in the non-neoadjuvant setting. Axillary lymph nodes are usually smaller and atrophic therefore more difficult to identify after neoadjuvant chemotherapy.
CHEMOTHERAPY-INDUCED MORPHOLOGIC CHANGES

Changes in Benign Breast Tissue
Benign breast tissue show significant atrophy of the terminal ductal lobular units (TDLU) after neoadjuvant chemotherapy [6] . This includes reduction of the lobular acini (Fig. 1) , lobular sclerosis and the attenuation of the lobular/ductal epithelium (Fig. 2) . The attenuation of the epithelial lining may make the myoepithelial cells appear prominent (Fig. 3) . Sometimes, there are scattered atypical epithelial cells in the TDLU containing variably enlarged hyperchromatic nuclei and vacuolated cytoplasm (Fig. 4) . Signs of cell proliferation are absent and there is no mitotic activity. Fig. (1) . The normal breast terminal ductal lobular unit (TDLU) shows atrophy and diminished acini unit after neoadjuvant chemotherapy (H&E, x100).
Fig. (2).
There is intralobular sclerosis and attenuation of the ductal/lobular epithelium (H&E, x400). Fig. (3) . The attenuation of the epithelium makes the myoepithelial cells appear prominent; not to be mistaken for lobular neoplasia. (H&E, x400). Fig. (4) . Neoadjuvant chemotherapy may make the epithelial cells of normal duct appear atypical containing enlarged nuclei, prominent nucleoli and vacuolated cytoplasm (H&E, x600). However, cell proliferation and mitotic activity are absent.
Changes in Breast Cancer
The neoadjuvant chemotherapy effect is recognized as a fibrous or fibromyxoid area containing patchy lymphocytes, histiocytes, and absence of normal breast ducts and TDLUs (Fig. 5) . Hemosiderin laden macrophages and foreign body giant cells are also present in the tumor bed representing previous biopsy site. When the tumor bed is extensively sampled and no tumor cells are identified, this is termed complete pathologic response.
If residual cancer cells are present, they may be seen as infiltrating cords and nests (Fig. 6) , or sparse and singly dispersed cells mimicking histiocytes. On the other hand, collections of histiocytes may resemble residual tumor cells. Immunohistochemical stains with cytokeratin and CD68 will help in differentiating tumor cells from histiocytes (Fig. 7) . Residual tumor nests may show marked retraction artifact in the fibrous stroma mimicking lymphovascular invasion; immunohistochemical stain for lymphatic channel marker D2-40 may be useful to distinguish tissue retraction from lymphatic invasion (Fig. 8) . Specimens containing residual tumor cells are labeled as showing signs of a partial pathologic response.
Residual cancer cells surviving chemotherapy may show a spectrum of changes, which are evident in the invasive as well as the in-situ component of the tumor. Most common chemotherapy effects include nuclear hyperchromasia, nuclear pleomorphism and cytoplasmic changes such as hypereosinophilic cytoplasm and vacuolization (Fig. 9) .
The size or extent of the residual breast cancer is measured as the largest contiguous focus of residual carcinoma or the number of tumor foci encompassing the area of tumor bed. The margins of residual tumor (DCIS and invasive carcinoma) should be evaluated and distance reported.
Changes in Lymph Nodes
Axillary lymph nodes may become small and atrophic after neoadjuvant chemotherapy. Microscopically, lymph nodes may show depletion of lymphocytes, fibrosis and collections of histiocytes (Figs. 10, 11) . The latter two features are indications of prior metastases that have responded completely to chemotherapy. Efforts should be made to identify residual tumor cells in these lymph nodes and report the presence or absence of treatment effects (Fig.  12) .
PATHOLOGY REPORT
The pathology report should be as detailed as possible. Many institutions are using a synoptic reporting format recommended by the Association of Directors of Anatomic and Surgical Pathology (ADASP) [7] . The American College of Surgeons-Commission on Cancer (ACS-CoC) requires that the pathology reports of institutions approved by them include scientifically validated data presented in a checklists, which have been approved and distributed by the College of American Pathologist on their website. Dynamic templates of such checklists have been developed to reduce reporting errors, improve work efficiency and increase compliance [8] . 
Grading of Pathologic Response
The degree of neoadjuvant chemotherapy effect should be assessed and reported because it has significant prognostic value. Several systems have been proposed to record pathologic response of breast cancer to treatment. We will briefly mention two systems here: the Miller-Payne grading system [9] and the one proposed by Pinder et al. [10] . It should be mentioned that all these systems need further approval for validity and reproducibility; they rely on extensive sampling of the tumor bed. Each institution should adopt a system to report the degree of treatment response of breast cancer to neoadjuvant chemotherapy in the pathology report.
Other Pathological Parameters
Other pathologic parameters that should be included in a pathology report after breast cancer neoadjuvant chemotherapy are the same as that for pretreatment breast cancer and include tumor type, size, grade, margins, and biomarkers (ER/PR/Her-2).
Staging
The current recommendation of the American Joint Committee on Cancer (AJCC) for staging of breast cancers is based on pretreatment examination and radiologic findings, and the postoperative pathologic assessment of the resected tumor and regional lymph nodes. Proposals have been made to modify this approach and use other systems for staging of tumors in patients who have received neoadjuvant chemotherapy [11] . However, as of today there is no consensus for a need to change the existing staging system or to develop a new staging system for tumors treated by neoadjuvant chemotherapy.
